Walmart’s Discount Insulin Could Attract Insured Customers

Walmart Inc. — which like Amazon has been diving deeper and deeper into health care — recently made one of its biggest moves yet in that space by partnering with Novo Nordisk to launch private-label insulin at a steeply discounted cash price. While the new offering still may be too expensive for some and likely won’t solve the overarching insulin-affordability problem, some observers say it’s indicative of how well-poised certain companies are to disrupt the health care industry’s least consumer-friendly practices.

“Insulin is, from a business point of view, attractive to competitors like Walmart — they see a product that has a very big audience that is grossly overpriced, where that audience is stressed and dissatisfied because they don’t believe they’re getting the value that they should be getting,” says Michael Abrams, a principal and co-founder at health care consulting firm Numerof & Associates.

About 34 million Americans, or just over 1 in 10, had diabetes as of 2020, according to the Centers for Disease Control and Prevention. The condition comes with estimated medical costs of around $9,601 per year, and the price of insulin has become a particular concern in recent years, with one study finding that the average price of an insulin prescription doubled between 2012 and 2016. Those high costs can be dangerous and even deadly, as news reports and research examining the practice of insulin rationing have illustrated.

© 2021 MMIT

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts
September 23

Experts: EU Will Continue to Beat US on Biosimilar Adoption

Read More
September 23

Pharma Industry Braces as Dems Hash Out Drug Price Package

Read More
September 23

Study Flags Potential Benefit of Targeted Medication Reviews

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today